Agilent Technologies, Inc. (NYSE:A) VP Sells $232,737.84 in Stock

Agilent Technologies, Inc. (NYSE:A) VP Rodney Gonsalves sold 1,908 shares of the company’s stock in a transaction on Monday, March 17th. The shares were sold at an average price of $121.98, for a total transaction of $232,737.84. Following the completion of the sale, the vice president now directly owns 21,786 shares in the company, valued at $2,657,456.28. This represents a 8.05 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Agilent Technologies Stock Down 1.6 %

Agilent Technologies stock opened at $120.23 on Friday. The company has a 50-day simple moving average of $137.07 and a 200-day simple moving average of $137.45. The firm has a market capitalization of $34.28 billion, a P/E ratio of 27.64, a P/E/G ratio of 3.45 and a beta of 1.11. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.66 and a current ratio of 2.20. Agilent Technologies, Inc. has a one year low of $117.17 and a one year high of $155.35.

Agilent Technologies (NYSE:A) last released its quarterly earnings results on Wednesday, February 26th. The medical research company reported $1.31 EPS for the quarter, topping the consensus estimate of $1.27 by $0.04. The business had revenue of $1.68 billion during the quarter, compared to analyst estimates of $1.67 billion. Agilent Technologies had a net margin of 19.27% and a return on equity of 25.56%. As a group, equities analysts expect that Agilent Technologies, Inc. will post 5.57 earnings per share for the current year.

Agilent Technologies Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 23rd. Investors of record on Tuesday, April 1st will be given a $0.248 dividend. The ex-dividend date is Tuesday, April 1st. This represents a $0.99 dividend on an annualized basis and a yield of 0.83%. Agilent Technologies’s dividend payout ratio is presently 22.76%.

Hedge Funds Weigh In On Agilent Technologies

Institutional investors and hedge funds have recently bought and sold shares of the stock. CKW Financial Group lifted its holdings in Agilent Technologies by 114.9% in the 4th quarter. CKW Financial Group now owns 187 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 100 shares during the last quarter. Global X Japan Co. Ltd. lifted its holdings in Agilent Technologies by 161.1% in the 4th quarter. Global X Japan Co. Ltd. now owns 188 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 116 shares during the last quarter. Redwood Park Advisors LLC acquired a new stake in Agilent Technologies in the 4th quarter valued at about $27,000. Lee Danner & Bass Inc. acquired a new stake in Agilent Technologies in the 4th quarter valued at about $29,000. Finally, Sunbelt Securities Inc. lifted its holdings in Agilent Technologies by 640.0% in the 4th quarter. Sunbelt Securities Inc. now owns 222 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 192 shares during the last quarter. Institutional investors own 87.42% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on A. Bank of America cut their price target on shares of Agilent Technologies from $153.00 to $150.00 and set a “neutral” rating on the stock in a report on Friday, December 13th. StockNews.com raised shares of Agilent Technologies from a “hold” rating to a “buy” rating in a report on Tuesday, December 24th. Citigroup upped their price target on shares of Agilent Technologies to $165.00 and gave the company a “buy” rating in a report on Thursday, December 19th. Barclays upgraded shares of Agilent Technologies from an “underweight” rating to an “equal weight” rating and boosted their target price for the company from $135.00 to $145.00 in a research note on Monday, February 10th. Finally, Wells Fargo & Company lowered their target price on shares of Agilent Technologies from $157.00 to $155.00 and set an “overweight” rating for the company in a research note on Monday, December 9th. Seven research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $146.15.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.